Document Type
Article
Publication Date
11-28-2025
Abstract
Teclistamab, a bispecific antibody targeting B-cell maturation antigen (BCMA), is effective in relapsed or refractory multiple myeloma (RRMM), but its impact on patients with soft tissue plasmacytomas is unclear. We studied 385 RRMM patients treated with teclistamab at 13 U.S. centers through September 2023, with follow-up to April 2024. Soft tissue plasmacytomas were classified as true extramedullary disease (EMD; not contiguous with bone) or paraskeletal plasmacytomas (PSK; contiguous with bone). Patients with the simultaneous presence of both were classified as true-EMD, reflecting its adverse prognosis. Of those, 109 (28%) had true EMD, 33 (9%) had PSK, and 243 (63%) had no soft tissue plasmacytoma (No-STP). Median follow-up was 9.9 months. Overall response rates were 38% in true-EMD, 54.1% in PSK, and 62.4% in No-STP (p < 0.001). Median progression-free survival (PFS) was 1.4 months in true-EMD, 6.51 months in PSK, and 8.95 months in No-STP (p < 0.0001). Median overall survival (OS) was 9.54 months for true EMD, 13.1 months for PSK, and not reached in No-STP (p = 0.00012). In multivariable analysis, true-EMD was independently associated with inferior PFS and OS, while PSK showed numerically lower outcomes. These findings highlight the need for tailored strategies in patients with soft tissue plasmacytomas, particularly those with true-EMD.
Recommended Citation
Afrough, Aimaz; Dima, Danai; Razzo, Beatrice; Goel, Utkarsh; Sannareddy, Aishwarya; Pasvolsky, Oren; Vazquez-Martinez, Mariola; Ferreri, Christopher; Banerjee, Rahul; Khouri, Jack; Davis, James; Gaballa, Mahmoud; Lieberman-Cribbin, Alex; Rana, Masooma; Julian, Kelley; Anwer, Faiz; Shune, Leyla; DeJarnette, Shaun; Grajales-Cruz, Ariel; Ouchveridze, Evguenia; De Avila, Gabriel; Susanibar-Adaniya, Sandra; Portuguese, Andrew; Schrum, Daniel; Eberwein, Erin; Hosoya, Hitomi; Mikkilineni, Lekha; Kaur, Gurbakhash; McGuirk, Joseph; Rossi, Adriana; Herr, Megan; Castaneda, Omar; Locke, Frederick; Raza, Shahzad; Lin, Yi; Atrash, Shebli; Sborov, Douglas; Voorhees, Peter; Richard, Shambavi; Garfall, Alfred; Sidana, Surbhi; Patel, Krina; Hansen, Doris; Cowan, Andrew; Anderson, Larry; and Lee, Hans, "The Impact of Extramedullary and Paraskeletal Plasmacytomas on Treatment Outcomes in Multiple Myeloma Treated With Teclistamab: U.S. Myeloma Immunotherapy Consortium Real-World Experience" (2025). Department of Medical Oncology Faculty Papers. Paper 323.
https://jdc.jefferson.edu/medoncfp/323
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
PubMed ID
41315206
Language
English
Comments
This article is the author’s final published version in Blood Cancer Journal, Volume 16, Issue 1, 2026, Article number 12.
The published version is available at https://doi.org/10.1038/s41408-025-01414-6. Copyright © The Author(s) 2025.